Cargando…

Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study

PURPOSE: The decision to prescribe packed red blood cell (PRBC) transfusions in patients with chemotherapy-induced anemia (CIA) includes assessment of clinical features such as the patient’s cancer type and treatment regimen, severity of anemia symptoms, and presence of comorbidities. We examined co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Granfortuna, James, Shoffner, Kaye, DePasquale, Stephen E., Badre, Sejal, Bohac, Chet, De Oliveira Brandao, Cisio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919983/ https://www.ncbi.nlm.nih.gov/pubmed/29349622 http://dx.doi.org/10.1007/s00520-017-4035-7

Ejemplares similares

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
por: Birgegård, Gunnar, et al.
Publicado: (2016)

Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON‐CLAD)
por: Makharadze, Tamta, et al.
Publicado: (2021)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
por: Boccia, Ralph V., et al.
Publicado: (2016)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

The selectin GMP-140 binds to sialylated, fucosylated lactosaminoglycans on both myeloid and nonmyeloid cells
Publicado: (1991)

TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
por: Brenet, Fabienne, et al.
Publicado: (2013)

Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer
por: Zheng, Ziming, et al.
Publicado: (2022)

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
por: Tsuboi, Shinya, et al.
Publicado: (2023)

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study
por: Mouysset, Jean-Loup, et al.
Publicado: (2016)

Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: a simulation study exploring underlying mechanisms
por: Middelburg, Rutger A, et al.
Publicado: (2018)

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
por: Tsuboi, Shinya, et al.
Publicado: (2023)

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
por: Papanicolas, Lito E., et al.
Publicado: (2021)

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy
por: Zecha, Judith A. E. M., et al.
Publicado: (2019)

Case Report: A Patient with COVID-19 under Myelosuppression Induced by Chemotherapy
por: Otsuka, Yuki, et al.
Publicado: (2020)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Factors Predicting Severe Myelosuppression and Its Influence on Fertility in Patients with Low-Risk Gestational Trophoblastic Neoplasia Receiving Single-Agent Methotrexate Chemotherapy
por: Tu, Xiaoyu, et al.
Publicado: (2020)

Anemia and RBC Transfusion
por: Marik, Paul Ellis
Publicado: (2009)

An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy
por: Baggott, Christina R., et al.
Publicado: (2010)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Cutting the brakes on hematopoietic regeneration by blocking TGFβ to limit chemotherapy-induced myelosuppression
por: Brenet, Fabienne, et al.
Publicado: (2015)

Ginsenoside Rg3 for Chemotherapy-Induced Myelosuppression: A Meta-Analysis and Systematic Review
por: Pan, Linlin, et al.
Publicado: (2020)

Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
por: Epstein, Robert S, et al.
Publicado: (2021)

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
por: Brugnatelli, S., et al.
Publicado: (1996)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Anemia and transfusion therapy: an update
por: Madrazo-González, Z., et al.
Publicado: (2011)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy-related myelosuppression
por: YAO, YI, et al.
Publicado: (2014)

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients
por: Tian, Huan, et al.
Publicado: (2015)

The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study
por: Ji, Yajie, et al.
Publicado: (2021)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Educational Case: Transfusion reactions: Transfusion associated circulatory overload vs transfusion-related acute lung injury
por: Desai, Diana S., et al.
Publicado: (2022)

Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework
por: Wang, Weijia, et al.
Publicado: (2021)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e5tthp2b7jg1ka9ifdfq0gmqdg